Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: sample size returned 65 record(s)
|
|
Sunday, 07/31/2016
|
Sample Size Calculations for Micro-Randomized Trials in MHealth
Peng Liao, University of Michigan; Ji Sun, University of Michigan; Susan A. Murphy, University of Michigan
|
Estimating Design Effects in Small Areas and Domains through Aggregation
Jerry Maples, U.S. Census Bureau
2:05 PM
|
Optimum Sample Size Allocation in Multilevel Disease Detection Problem
Yinan Fang, Iowa State University; Chong Wang, Iowa State University; Jeffrey Zimmerman, Iowa State University
3:35 PM
|
Bayesian Clinical Trial Design for Survival Studies with Historical Study Data Under a Proportional Hazards Assumption
Matthew Psioda, The University of North Carolina at Chapel Hill; Joseph G. Ibrahim, The University of North Carolina at Chapel Hill
4:35 PM
|
|
Monday, 08/01/2016
|
Optimal Sample Size Determination for Adaptive Seamless Phase II/III Design
Zhongying Xu, University of Pittsburgh ; John A. Kellum, University of Pittsburgh; Gary M. Marsh, University of Pittsburgh ; Chung-Chou H. Chang, University of Pittsburgh
|
Sample Size and Duration of Study in Clinical Trials with Time-to-Event Endpoint
Ryunosuke Machida, Tokyo University of Science; Yosuke Fujii, Pfizer Japan; Takashi Sozu, Tokyo University of Science
|
Best Practices for Interim Analysis in Clinical Trials
Jiang Hu, FDA
|
Tolerance Cpk Contours: A New Tool to Enable Specification Setting in Development
Yuanyuan Duan, AbbVie; Russell L. Hertzler, AbbVie; Lanju Zhang, AbbVie; Dennis A. Stephens, AbbVie; David W. Werst, AbbVie; Paul A. David, AbbVie; Jie Zheng, AbbVie; Jian-Hwa H. Han, AbbVie
|
Internal Pilot Design for Clinical Trials with Repeated Measures
Xinrui Zhang; Yueh-Yun Chi, University of Florida
|
Assessment of Effect Size and Power for Survival Analysis Through a Binary Surrogate Endpoint in Clinical Trials
Judah Abberbock, University of Pittsburgh ; Gong Tang, University of Pittsburgh
|
Unified Definition of Effect Size and Universal Labeling of Its Magnitude
Panduan An, Ohio University; Wei Lin, Ohio University
|
Testing the Sphericity of a Covariance Matrix When the Dimension Is Much Larger Than the Sample Size
Zeng Li, The University of Hong Kong
|
Testing the Sphericity of a Covariance Matrix When the Dimension Is Much Larger Than the Sample Size
Zeng Li, The University of Hong Kong
8:55 AM
|
On Exact Sample Size of K-Stage Group Sequential Designs for Rare Diseases
Man Jin
9:20 AM
|
Bayesian Adaptive Design for Trials with Delayed Binary Outcome Using Historical Control Data
Nusrat Harun, Cincinnati Children's Hospital ; Mi-Ok Kim, Cincinnati Children's Hospital Medical Center; Chunyan Liu, Cincinnati Children's Hospital
9:35 AM
|
Sample-Size Calculations for Stratified Micro-Randomized Trials in Mhealth
Walter Dempsey, University of Michigan; Peng Liao, University of Michigan; Susan A. Murphy, University of Michigan
10:50 AM
|
Unified Definition of Effect Size and Universal Labeling of Its Magnitude
Panduan An, Ohio University; Wei Lin, Ohio University
10:55 AM
|
The Design of Cluster-Randomized Trials Using Robust Methods for Right- and Interval-Censored Event Times
Yujie Zhong, Cambridge Institute of Public Health; Richard John Cook, University of Waterloo
11:25 AM
|
|
Tuesday, 08/02/2016
|
Bayesian Approach to Sample Size Determination for Multilevel Logistic Regression Models with Misclassified Outcomes
Tyler Nelson, Baylor University
|
Optimal Stratification of Univariate Populations via StratifyR Package
Karuna Garan Reddy, University of the South Pacific; Mohammed G. M. Khan, University of the South Pacific
|
Sample Size Study for Measurement Systems Analysis Models
Laura Lancaster, SAS Institute; Chris Gotwalt, SAS Institute
8:35 AM
|
Operating Characteristic Curves for K-Factors of Normal Tolerance Intervals
Derek Young, University of Kentucky
9:20 AM
|
Power Analysis for RNA-Seq Differential Expression Studies
Lianbo Yu, The Ohio State University; Soledad Fernandez, The Ohio State University; Guy N. Brock, The Ohio State University
10:50 AM
|
Case Study: How Promising Is the VALOR Trial for the Future of Adaptive Designs?
Yannis Jemiai, Cytel
10:55 AM
|
Optimal Stratification of Univariate Populations via StratifyR Package
Karuna Garan Reddy, University of the South Pacific; Mohammed G. M. Khan, University of the South Pacific
12:00 PM
|
Sample Size Optimization of the Consumer Price Index: An Implementation Using R
Harold Gomes, Bureau of Labor Statistics; William Johnson, Bureau of Labor Statistics
2:20 PM
|
Sample Size Estimation Using a Hybrid Classical and Bayesian Procedure
Maria Ciarleglio, Yale University; Christopher Arendt, Air Force Office of Scientific Research
2:20 PM
|
Using Power Contours to Assess the Sensitivity of Clinical Trial Design Assumptions
Richard C. Zink, JMP Life Sciences, SAS Institute; Xiaotong Jiang, The University of North Carolina at Chapel Hill
2:35 PM
|
On Power and Sample Size of the ANOVA-Type Rank Test
Chunpeng Fan, Sanofi US; Donghui Zhang, Sanofi US
2:50 PM
|
Power Analysis for Longitudinal Data
Niloofar Ramezani, University of Northern Colorado
2:50 PM
|
Identifying Main Effects in Multi-Factor Clinical Trials
Abhishek Bhattacharjee, University of Florida; Samuel S. Wu, University of Florida
3:05 PM
|
Two-Stage Procedure for Fixed-Width Confidence Intervals of the Risk Ratio
Hokwon Cho, University of Nevada, Las Vegas
3:20 PM
|
|
Wednesday, 08/03/2016
|
Best Practices for Discussing/Negotiating Endpoints, Hypotheses, Sample Size, and Other Study Design Aspects of Clinical Studies with FDA Reviewers
Jennifer Mischke, NAMSA; Tyson Rogers, NAMSA
|
Sampling with Minimal Strata Sample Size Requirements
Stanislav Kolenikov, Abt SRBI; Igor Griva, George Mason University
|
Accuracy in Effect Size Estimation for IID Observations
Francis Bilson Darku, The University of Texas at Dallas; Ken Kelly, Mendoza College of Business; Bhargab Chattopadhay, The University of Texas at Dallas
|
Incorporating Biological Information in Sparse Principal Component Analysis with Application to Genomic Data
Ziyi Li, Emory University; Qi Long, Emory University; Sandra Safo, Emory University
8:35 AM
|
Unblinded Sample Size Re-Estimation in Bioequivalence Trials with Small Sample Sizes
Sam Hsiao, Cytel; Lingyun Liu, Cytel
8:35 AM
|
Accuracy in Effect Size Estimation for IID Observations
Francis Bilson Darku, The University of Texas at Dallas; Ken Kelly, Mendoza College of Business; Bhargab Chattopadhay, The University of Texas at Dallas
8:45 AM
|
Sampling with Minimal Strata Sample Size Requirements
Stanislav Kolenikov, Abt SRBI; Igor Griva, George Mason University
8:50 AM
|
Sample Size Planning for Survival Endpoints in Cardiovascular Clinical Trials
Ququan Liu, FDA/CDER; John Lawrence, FDA/CDER; Hsien-Ming James Hung, FDA
8:50 AM
|
Adaptive Multi-Arm Multi-Stage Group Sequential Designs
Cyrus Mehta, Cytel; Pranab Ghosh, Cytel
9:00 AM
|
Blinded Sample Size Re-Estimation in Demonstrating Biosimilarity
Lingyun Liu, Cytel; Emmanuelle Vincent, Cytel
9:05 AM
|
Sample Size Re-Estimation in a Two-Stage Cross-Over Trial for Testing for Average Bioequivalence
Byron Jones, Novartis Pharma; Will Maurer, Novartis Pharma AG; Ying Chen, Shanghai University of Finance and Economics
9:20 AM
|
An Extrapolation Framework to Specify Requirements for Drug Development in Children
Gerald Hlavin, Medical University of Vienna; Franz Koenig, Medical University of Vienna; Christoph Male, Medical University of Vienna; Martin Posch, Medical University of Vienna; Peter Bauer, Medical University of Vienna
9:35 AM
|
Adaptive Enrichment with Subpopulation Selection at Interim
Xiang Ling, FDA/CDER; Sue-Jane Wang, FDA; Kun Jin, FDA/CDER; Hsien-Ming James Hung, FDA
9:35 AM
|
Weighted Estimation in Confounded Binary Data Subject to Outcome Misclassification
Christopher A. Gravel, McGill University; Robert W. Platt, McGill University
9:35 AM
|
Improved Group Sequential Clinical Trial Designs with Multiple Co-Primary Endpoints
Koko Asakura, National Cerebral and Cardiovascular Center; Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center; Franz Koenig, Medical University of Vienna; Martin Posch, Medical University of Vienna
9:50 AM
|
Bayesian Design of Phase II Noninferiority (NI) Safety Clinical Trial
Lu-May Chiang, Novartis Pharma; David Ohlssen, Novartis; Dong Xi, Novartis
11:20 AM
|
The Interplay Between Sample Size and Reproducibility of Results in fMRI Studies
Han Bossier, Ghent University; Ruth Seurinck, Ghent University; Sanne Roels, Ghent University; Simone Kuehn, MPI for Human Development; Jean-Baptiste Poline, University of California at Berkeley; Beatrijs Moerkerke, Ghent University
11:20 AM
|
Current Population Survey Sample Size Study
Daniel Sommers, U.S. Census Bureau; Stephanie Chan Yang, U.S. Census Bureau; Yang Cheng, U.S. Census Bureau
2:05 PM
|
Using Adaptive Designs to Avoid Selecting the Wrong Arms in a Comparative Effectiveness Trial
Byron Gajewski, University of Kansas Medical Center
2:50 PM
|
The Statistical Power of One-Sample Location Hypothesis Tests
Timothy Hall, PQI Consulting
2:50 PM
|
Robust Variance Estimation in Meta-Regression: Adjustments for Small and Moderate Sample Sizes
Elizabeth Tipton, Columbia University; James Eric Pustejovsky, The University of Texas at Austin
3:20 PM
|
Change-Plane Analysis for Subgroup Detection and Sample Size Calculation
Ailin Fan, North Carolina State University; Rui Song, North Carolina State University; Wenbin Lu, North Carolina State University
3:20 PM
|
Sample Size Planning of Two-Arm Trials Generating Discrete Quantitative Data to Be Analyzed by Means of the Mann-Whitney-Wilcoxon Statistic
Stefan Wellek, CIMH/University of Heidelberg
3:35 PM
|
|
Thursday, 08/04/2016
|
Simplified Tools for Sample Size Determination for Correlation Coefficient Inference
Stephen W. Looney, Augusta University; Justine May, Augusta University; Jessica McKinney Ketchum, Craig Hospital
9:05 AM
|
Subgroup Identification and Sample-Size Calculation for the Proportional Hazard Model
Suhyun Kang, North Carolina State University ; Wenbin Lu, North Carolina State University
9:35 AM
|
Asymmetric Margins for Equivalence Tests
Somesh Chattopadhyay
10:05 AM
|
Design Immunotherapy Trials with Delayed Treatment Effect
Zhenzhen Xu, FDA; Boguang Zhen, FDA; Yongseok Park, University of Pittsburgh; BIN ZHU, National Cancer Institute
10:35 AM
|
Study Design for Interval-Censored Outcomes
Yibai Zhao, University of Massachusetts - Amherst; Xiangdong Gu, University of Massachusetts - Amherst; Raji Balasubramanian, University of Massachusetts - Amherst
10:50 AM
|
Sample Size Methods for Validating Treatment Selection Cancer Biomarkers from Right-Censored Survival Data
Kevin Dobbin, University of Georgia; Lisa M. McShane, National Cancer Institute
11:05 AM
|
Comparison Beyond Power: Sample Size Re-Estimation vs. Group Sequential Design
Lei Shu, Astellas Pharma; Charles Liu, Astellas Pharma; Matt Rosales, Astellas Pharma
11:05 AM
|
Randomization Ratio in Survival Trials
Jingyuan Wang, Radiushealth
11:15 AM
|
Debiasing Regularized Estimators with High-Dimensional Data
Cun-Hui Zhang, Rutgers University
11:25 AM
|
Weighting for Nonresponse in the Overseas Citizen Population Survey: The Effects of Sample Size and Adjustment Method on Accuracy of Estimates
Jonathan Mendelson, Fors Marsh Group; Pengyu Huang, Fors Marsh Group
11:50 AM
|
|
|
